Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 530,200 shares, a growth of 8.1% from the November 30th total of 490,400 shares. Currently, 9.0% of the company's shares are sold short. Based on an average daily volume of 28,200 shares, the short-interest ratio is presently 18.8 days.
Institutional Trading of Greenwich LifeSciences
A number of large investors have recently made changes to their positions in GLSI. Rhumbline Advisers acquired a new position in shares of Greenwich LifeSciences during the second quarter worth about $117,000. Bank of New York Mellon Corp acquired a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth about $264,000. Garden State Investment Advisory Services LLC acquired a new position in Greenwich LifeSciences in the 3rd quarter valued at $253,000. Barclays PLC lifted its position in Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company's stock worth $123,000 after buying an additional 6,538 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after acquiring an additional 5,861 shares during the last quarter. 4.16% of the stock is owned by institutional investors and hedge funds.
Greenwich LifeSciences Stock Up 2.9 %
NASDAQ:GLSI traded up $0.32 on Wednesday, reaching $11.23. The company's stock had a trading volume of 42,190 shares, compared to its average volume of 39,041. The stock has a 50 day moving average price of $13.29 and a 200 day moving average price of $14.27. Greenwich LifeSciences has a 12-month low of $8.00 and a 12-month high of $21.44. The firm has a market cap of $147.62 million, a price-to-earnings ratio of -14.04 and a beta of 1.61.
About Greenwich LifeSciences
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Stories
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
